Search

Displaying results 3811 - 3820 of 7502 in total
  1. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  2. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

  3. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.

  4. Drug

    Rice bran oil

    go.drugbank.com/drugs/DB11293
    ApprovedInvestigational

    Rice bran oil is classified as an indirect additive used in food contact substances by the FDA.

  5. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  6. Drug

    Diazepinomicin

    go.drugbank.com/drugs/DB12420
    Investigational

    Discovered using Thallion’s DECIPHER technology, diazepinomicin has completed preclinical studies conducted by the National Cancer Institute and Thallion to establish safety and efficacy in animal and … Diazepinomicin is a natural product derived from a non-pathogenic micro-organism.

  7. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  8. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection. … being acquired by Implicit Bioscience in 2005.

  9. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. … It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.

  10. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues